Please login to the form below

Not currently logged in
Email:
Password:

Scott Whitcup joins Questcor’s board of directors

Allergan’s chief scientific officer to help expand Acthar’s use to treat autoimmune conditions

Scott Whitcup - Questcor PharmaceuticalsScott Whitcup, executive VP of R&D and chief scientific officer at Amgen, has joined the board of directors at Questcor Pharmaceuticals.

The company said his experience in commericialising Botox as a treatment for chronic migraine, upper limb spasticity and neurogenic urologic conditions would be beneficial in Questcor's efforts to expand the uses of its own Acthar Gel brand to treat autoimmune conditions.

“The growth strategies and product manufacturing for Acthar and Botox have some interesting parallels,” said Questcor's chair, Virgil Thompson.

Acthar is currently approved in the US in several indications, including infantile spasms; exacerbations of multiple sclerosis in adults; nephrotic syndrome; and several rheumatic disorders including collagen diseases; dermatologic diseases and ophthalmic diseases.

Whitcup joined Allergan in 2000, becoming executive VP of R&D in 2004 and chief scientific officer in 2009.

Other products he has helped bring to market at Allergan include Lumigan, Restasis and Latisse.

Prior to joining Allergan Whitcup served as clinical director at the National Institutes of Health's National Eye Institute, where he help develop new therapies for ophthalmic diseases

22nd February 2012

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
IGNIFI

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

The Patient Will See You Now – The Evolution of the Doctor-Patient Relationship
The doctor-patient relationship is an ever changing one that changes as society changes. Technology then helps to drive this change along with a wide number of other factors....
Mind the Gap – Challenging Immunisation Apathy and Misinformation
world, the biggest challenges remain apathy and misinformation. Since a measles vaccine was introduced in the UK in 1968, Public Health England estimates that 20 million measles cases and 4,500...
Towards Better HCP Engagement – An Email Masterclass
6% of HCPs prefer being contacted by email, compared to 17% who favour the second most popular option: direct interaction with reps....